HIGHLIGHTS
SUMMARY
The ESCMID guidelines recommend considering bezlotoxumab in addition to standard-of-care antibiotics for the treatment of a second or further rCDI. Search strategy and Article Identification Published articles (from June 2017 to November 2020) assessing the efficacy and safety of bezlotoxumab for the prevention of rCDI after a first CDI episode were identified through computerized literature searches using PubMed until 31 August 2022. A combination of the following search terms was used: Quantitative and qualitative information from the included studies was summarized by means of textual descriptions. Studies Description Figure 1 shows the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.